Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans
- 30 May 2000
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 10 (4)
- https://doi.org/10.1016/s0928-0987(00)00092-0
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Simulation of Clinical TrialsAnnual Review of Pharmacology and Toxicology, 2000
- Pharmacokinetic/Pharmacodynamic Modeling in Drug DevelopmentAnnual Review of Pharmacology and Toxicology, 2000
- Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.Journal of Clinical Oncology, 1998
- An Evaluation of the Integration of Pharmacokinetic and Pharmacodynamic Principles in Clinical Drug DevelopmentClinical Pharmacokinetics, 1997
- Learning versus confirming in clinical drug development*Clinical Pharmacology & Therapeutics, 1997
- Preliminary Pharmacokinetics and Pharmacodynamics of an Ultra-Short-Acting OpioidAnesthesia & Analgesia, 1993
- The Pharmacokinetics of the New Short-acting Opioid Remifentanil (GI87084B) in Healthy Adult Male VolunteersAnesthesiology, 1993
- Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug developmentClinical Pharmacology & Therapeutics, 1992
- Pharmacokinetics, Pharmacodynamics, and Rational Opioid SelectionAnesthesiology, 1991
- Pharmacologically Guided Phase I Clinical Trials Based Upon Preclinical Drug DevelopmentJNCI Journal of the National Cancer Institute, 1990